Baidu
map

Lancet Infectious Diseases:检验人“找虫”“找菌”的故事双双登上顶级医学期刊

2022-07-04 “检验医学”公众号 “检验医学”公众号

根据2022年期刊引证报告(JCR),《柳叶刀-感染病学》在国际感染病学期刊中排名第一,影响因子71.421,是全球公认的最高质量、最具权威的感染病学杂志。

南宁检验人“找虫”的故事

由南宁市第四人民医院罗晓成、李莎、李倩为共同第一作者,罗晓璐为通讯作者等人组成的科研团队撰写的病例报道《Atypical Imported Loiasis Characterized by Recurrent Anemia in a Patient from China(以反复贫血为特征的不典型输入性罗阿丝虫病)》在国际顶级医学期刊《The Lancet Infectious Diseases(柳叶刀-感染病学)》杂志上发表。

The Lancet Infectious Diseases杂志截图

根据2022年期刊引证报告(JCR),《柳叶刀-感染病学》在国际感染病学期刊中排名第一,影响因子71.421,是全球公认的最高质量、最具权威的感染病学杂志。

《广西日报》日前撰文特别介绍了该病例的详细诊疗过程。

病例报道了一位49岁的男性,因反复头晕、乏力1年余入院。此前患者有多年在加纳、刚果共和国、厄瓜多尔的务工经历。入院前多次检查有不同程度贫血,曾接受4次输血治疗。近两年时间里,患者跑了多家医院,诊断为“溶血性贫血、疟疾可能性大、重度贫血、脾肿大、慢性胃炎、华支睾吸虫感染”等,并接受抗疟治疗,但是疗效不明显,贫血依然反复出现,不舒服的症状无法消除。

2021年3月,患者入住南宁市四医院后,在白天和晚上采集的外周血涂片上均可查见微丝蚴。然而确定是什么丝虫,医务人员却经历了一个多月形态学和PCR的反复基因测序,对看到的反复求证,对检验结果小心存疑,查阅国内外医学文献,回访患者就医医院,完善所有医学依据,最终确诊为是一种罕见的寄生虫病:罗阿丝虫病。之后在四医院接受了抗丝虫治疗,2周后复诊时外周血微丝蚴明显减少,6周后复诊,外周血未查见微丝蚴,临床症状消失,血红蛋白恢复正常。

2007年,我国成为全球第一个宣布消除丝虫病的国家。对于罗阿丝虫病,我国近年来偶有输入性病例报道。其典型症状是感染者皮肤上有游走性肿块,眼部有时可见成虫蠕动,皮肤瘙痒等。但是本例患者缺乏以上典型症状。

因此诊断为罗阿丝虫病并成功救治,是一例非流行区域、非典型症状的准确诊断。这其中,医务工作者对病因穷追不舍的态度是找到虫子、辨别虫子的关键。这个案例刊登于世界一流的医学期刊,为全球范围内丝虫病的诊断提供了宝贵的文献记载。

河北检验人“找菌”的故事

由河北省胸科医院检验科郑立恒主任检验师撰写的《A case of Tsukamurella pneumonia misdiagnosed as pulmonary tuberculosis(一列误诊为肺结核的冢村菌肺炎病例报道)》在国际顶级医学期刊《The Lancet Infectious Diseases(柳叶刀-感染病学)》上发表。

文章报道一名间质性肺炎长期应用激素治疗的72岁男性患者因肺部感染、液气胸在两家医院多次住院发现痰抗酸染色阳性诊断为肺结核,经抗痨治疗9个月未见好转,后因胸腔置管长期流脓,造成置管部位胸壁软组织溃烂入我院,再次送痰抗酸染色,郑立恒教授敏锐地发现其中的抗酸菌虽然和结核分枝杆菌十分相似,但却有细微差别,部分菌有细小分枝(图1),经培养(图2)后鉴定为耐酪氨酸冢村菌。

图1:油镜下痰抗酸染色冢村菌形态特征

图2:冢村菌菌落形态(箭头所示)

冢村菌属属于诺卡菌科,革兰阳性、弱或不定抗酸、专性需氧的不规则杆菌,该菌属1988年建立,目前微生物实验室中传统的表型方法和试剂盒无法将冢村菌与其他抗酸菌(如结核分枝杆菌、非结核分枝杆菌、诺卡菌、马红球菌和戈登菌等)区分开来。国内没有冢村菌相关临床病例的报道,国际上相关文献极少,且从未见到原始标本涂片染色中此菌形态的展示,此论文在世界权威杂志首次报道了痰中冢村菌的形态特征,打破了人们对抗酸菌的固有认知,对少见抗酸菌的鉴别诊断具有重要的临床价值和里程碑式的意义。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013918, encodeId=779b2013918f4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jul 13 10:18:10 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831602, encodeId=97b01831602d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jun 18 16:18:10 CST 2023, time=2023-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513923, encodeId=5b3f151392373, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541725, encodeId=72501541e25b1, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569799, encodeId=a91a1569e9995, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244039, encodeId=37ff12440391e, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Sun Jul 03 21:18:10 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013918, encodeId=779b2013918f4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jul 13 10:18:10 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831602, encodeId=97b01831602d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jun 18 16:18:10 CST 2023, time=2023-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513923, encodeId=5b3f151392373, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541725, encodeId=72501541e25b1, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569799, encodeId=a91a1569e9995, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244039, encodeId=37ff12440391e, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Sun Jul 03 21:18:10 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
    2023-06-18 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013918, encodeId=779b2013918f4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jul 13 10:18:10 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831602, encodeId=97b01831602d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jun 18 16:18:10 CST 2023, time=2023-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513923, encodeId=5b3f151392373, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541725, encodeId=72501541e25b1, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569799, encodeId=a91a1569e9995, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244039, encodeId=37ff12440391e, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Sun Jul 03 21:18:10 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013918, encodeId=779b2013918f4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jul 13 10:18:10 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831602, encodeId=97b01831602d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jun 18 16:18:10 CST 2023, time=2023-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513923, encodeId=5b3f151392373, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541725, encodeId=72501541e25b1, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569799, encodeId=a91a1569e9995, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244039, encodeId=37ff12440391e, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Sun Jul 03 21:18:10 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
    2022-07-05 Tamikia
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013918, encodeId=779b2013918f4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jul 13 10:18:10 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831602, encodeId=97b01831602d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jun 18 16:18:10 CST 2023, time=2023-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513923, encodeId=5b3f151392373, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541725, encodeId=72501541e25b1, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569799, encodeId=a91a1569e9995, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244039, encodeId=37ff12440391e, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Sun Jul 03 21:18:10 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
    2022-07-05 dongjia2015
  6. [GetPortalCommentsPageByObjectIdResponse(id=2013918, encodeId=779b2013918f4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jul 13 10:18:10 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831602, encodeId=97b01831602d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Jun 18 16:18:10 CST 2023, time=2023-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513923, encodeId=5b3f151392373, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541725, encodeId=72501541e25b1, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569799, encodeId=a91a1569e9995, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Tue Jul 05 09:18:10 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244039, encodeId=37ff12440391e, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Sun Jul 03 21:18:10 CST 2022, time=2022-07-03, status=1, ipAttribution=)]
    2022-07-03 younei

    lancet上果然牛,感谢梅斯更新及时

    0

相关资讯

NEJM:非发达地区初级医疗机构结核病现场诊断的可行性研究

在乌干达社区医疗中心开展结核病现场分子检测和治疗大幅提高了患者诊断率及治疗率,对消除非发达地区结核病负担发挥关键作用

CMI:中国东部地区肺结核再感染率与复发率

我国东部地区肺结核治疗后前两年,内源性复发明显多于外源性再感染。

Thorax:肺结核与气流阻塞和小气道功能障碍的关系

结核病与肺功能损害呈正相关,并导致频繁的呼吸道症状。在来自结核病高负担国家的患者中,结核病应被视为气流阻塞和呼吸道症状的一个潜在重要危险因素。

Radiology:人工智能,实现肺结核的自动检测、诊断和严重程度的评估

结核病(TB)是一种由分枝杆菌引起的空气传播的传染病。现阶段,尽管与结核病相关的发病率和死亡率在全球范围内持续逐步下降,但在结核病流行的国家,该疾病的负担仍然很大。

CT诊断肺结核宝典:这是我见过的理想的经验总结!

为什么经验丰富的医生一看CT就知道是肺结核?因为肺结核的CT很有特点!

科室宣教:与肺结核病人密切接触该咋办

肺结核,又名肺痨,是发生在肺组织、气管、支气管和胸膜的结核病变。这一贯穿人类历史的病种,因为其曾经给人类带来的死亡率及病痛煎熬,一度让人谈“痨”色变。

Baidu
map
Baidu
map
Baidu
map